Clinical Study

The Effects of Pioglitazone on Biochemical Markers of Bone Turnover in the Patients with Type 2 Diabetes

Table 1

Changes of metabolic profiles and bone turnover markers after pioglitazone treatment.

Overall ( )Male ( )Female ( )
Before therapyAfter therapyBefore therapyAfter therapyBefore therapyAfter therapy

Age (yr)
Duration (yr)
BMI (kg/m2)
FBG (mmol/L)
HbA1c (%)
BMI (kg/m2)
SBP (mmHg)
DBP (mmHg)
T-CHO (mmol/L)
TG (mmol/L)
HDL-C (mmol/L)
LDL-C (mmol/L)
Ca2+ (mmol/L)
P3− (mmol/L)
BAP (μgU/L) 12.9 ± 3.8
P1NP (μg/L)
OC (ng/mL)
CTX (ng/mL)

Data are mean ± SD. ; , compared to before therapy. FBG: fasting blood glucose; BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; T-CHO: total cholesterol; TG: triglycerides; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; BAP: bone-specific alkaline phosphatase; P1NP: procollagen type 1 N-terminal propeptide; OC: osteocalcin; CTX: C-terminal telopeptide of type 1 collagen.